Christoph Boesecke, Jürgen K. Rockstroh – 25 September 2018

James A. Heslop, Stephen A. Duncan – 25 September 2018 – The use of pluripotent stem cells (PSCs) has transformed the investigation of liver development and disease. Clinical observations and animal models have provided the foundations of our understanding in these fields. While animal models remain essential research tools, long experimental lead times and low throughput limit the scope of investigations.

James A. Heslop, Stephen A. Duncan – 25 September 2018 – The use of pluripotent stem cells (PSCs) has transformed the investigation of liver development and disease. Clinical observations and animal models have provided the foundations of our understanding in these fields. While animal models remain essential research tools, long experimental lead times and low throughput limit the scope of investigations.

Takahiro Suda, Tomohide Tatsumi, Akira Nishio, Tadashi Kegasawa, Teppei Yoshioka, Ryoko Yamada, Kunimaro Furuta, Takahiro Kodama, Minoru Shigekawa, Hayato Hikita, Ryotaro Sakamori, Takasuke Fukuhara, Yoshiharu Matsuura, Tetsuo Takehara – 25 September 2018 – Natural killer cells (NK cells) play an essential role in the immunological mechanism underlying chronic hepatitis C (CHC). Impairment of NK cell function facilitates persistent infection with hepatitis C virus (HCV) and hepatocellular carcinogenesis.

Sanghoon Lee, Ping Zhou, Anita Gupta, Soona Shin – 25 September 2018 – While reactive ductules (RDs) have been observed in viral hepatitis, biliary atresia, nonalcoholic fatty liver disease, and adult hepatocellular carcinoma (HCC), RDs in pediatric liver cancer remain uncharacterized. This study investigated the relationship of RDs with angiogenic paracrine factors, the extent of angiogenesis, and tumor cell proliferation in pediatric hepatoblastoma (HBL)/HCC livers.

Tian‐Qi Zhang, Qun‐Qing Su, Xiao‐Ying Huang, Jin‐Guang Yao, Chao Wang, Qiang Xia, Xi‐Dai Long, Yun Ma – 24 September 2018 – Our previous reports have shown that microRNA‐4651 is a potential early diagnostic and prognostic marker for hepatocellular carcinoma. We aimed to investigate whether microRNA‐4651 modified postoperative adjuvant transarterial chemoembolization (pa‐TACE) to improve the prognosis of hepatocellular carcinoma.

Nicole J. Kim, Catherine Magee, Cassie Cummings, Helen Park, Mandana Khalili – 24 September 2018 – Recent hepatitis C virus (HCV) guidelines recommend disease monitoring and hepatocellular carcinoma (HCC) screening in patients with advanced fibrosis after a sustained virologic response (SVR) with direct‐acting antiviral (DAA) therapy. However, data on practice patterns in this setting is lacking. We aimed to characterize disease monitoring and HCC screening practices post‐SVR in an underserved HCV‐infected cohort.

24 September 2018

Omer Shahab, Rakesh Biswas, James Paik, Haley Bush, Pegah Golabi, Zobair M. Younossi – 24 September 2018 – Dyslipidemia is one of the common risk factors for NAFLD and is associated with cardiovascular (CV) mortality, which is the most common cause of death in NAFLD. Lipid‐lowering agents (LLAs) are used to reduce CV events in the general population. Our aim was to assess whether the use of LLAs in patients with NAFLD can reduce the risk of CV mortality. We used the third National Health and Nutrition Examination Survey mortality linked files.

Courtney B. Sherman, Spencer Behr, Jennifer L. Dodge, John P. Roberts, Francis Y. Yao, Neil Mehta – 24 September 2018 – Differentiating tumor versus bland portal vein thrombosis (PVT) is essential in determining liver transplantation (LT) candidacy for patients with hepatocellular carcinoma (HCC). We aimed to evaluate radiographic and clinical features that could noninvasively distinguish tumor PVT from bland PVT in HCC patients. Of 467 patients with HCC listed for LT from 2004 to 2011, 59 (12.6%) had PVT and 12 of 59 (20.3%) were deemed malignant.